Bipolar Depression Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Bipolar Depression pipeline constitutes 6+ key companies continuously working towards developing 6+ Bipolar Depression treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Bipolar Depression Overview
Bipolar disorder is a disabling chronic disease in which depression usually presents a higher risk of long-term functional impairment than mania. Persistent depression does not have a known cause. As with bipolar disorder, depression has hereditary factors and might also involve neurotransmitter imbalances in the brain. Depression associated with bipolar disorder may be more difficult to treat and require a customized treatment plan.

"Bipolar Depression Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Depression Market.

The Bipolar Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bipolar Depression Pipeline Report: https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Companies across the globe are diligently working toward developing novel Bipolar Depression treatment therapies with a considerable amount of success over the years. Bipolar Depression Key players such as - Clexio Biosciences, Iltoo Pharma, SAGE Therapeutics, NeuroRx, Inc., Sumitomo Dainippon Pharma, and others are developing therapies for Bipolar Depression treatment
Bipolar Depression Emerging therapies such as - CLE-100, ILT101, Zuranolone, NRX101, NRX100, Inc., SEP-4199, and others are expected to have a significant impact on the Bipolar Depression market in the coming years.
In May 2018, United States FDA awarded a Special Protocol Agreement (SPA) letter to NeuroRx, a clinical-stage biopharmaceutical company, forNRX-101, the first drug regimen designed to treat patients with severe bipolar depression and acute suicidal ideation and behavior
In December 2019, NeuroRx initiated a multi-center, randomized, stratified, double-blind, adaptive trial conducted under a Special Protocol Agreement with the FDA that enrolls patients demonstrating successful response in NCT03396601.Randomization will be 2:1 favoring NRX-101 (n=48) vs. lurasidone alone (n=24). The main objective is to test the hypothesis that following a successful response to a single infusion of ketamine (NRX-100), treatment with NRX-101 is superior to lurasidone in maintaining improvement in symptoms of depression as measured by the MADRS-10 total score.
In December 2020, Big Rock Partners Acquisition Corp. announced that it entered into an Agreement and Plan of Merger withNeuroRx, Inc. Under the terms of the transaction, Big Rock and NeuroRx will merge, and the company is expected to continue to trade on the Nasdaq Stock Market under the symbol "NRXP."
In January 2022, NeuroRx initiated a multi-center, randomized, double-blind trial in which patients with moderate levels of bipolar depression (MADRS >20) and sub-acute levels of suicidal ideation (C-SSRS 2 or 3) are randomized to receive twice-daily oral NRX-101 or lurasidone (standard of care).

Bipolar Depression Pipeline Therapeutics Assessment
Bipolar Depression Assessment by Product Type
Bipolar Depression By Stage and Product Type
Bipolar Depression Assessment by Route of Administration
Bipolar Depression By Stage and Route of Administration
Bipolar Depression Assessment by Molecule Type
Bipolar Depression by Stage and Molecule Type

DelveInsight's Bipolar Depression Report covers around 6+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Emerging Bipolar Depression Drugs Under Different Phases of Clinical Development Include:
CLE-100: Clexio Biosciences
ILT101: Iltoo Pharma
Zuranolone: SAGE Therapeutics
NRX101: NeuroRx, Inc.
NRX100: NeuroRx, Inc.
SEP-4199: Sumitomo Dainippon Pharma

Request for Sample PDF Report for Bipolar Depression Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Pipeline Analysis:
The Bipolar Depression pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the Bipolar Depression treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bipolar Depression Treatment.
Bipolar Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Bipolar Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Bipolar Depression market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Bipolar Depression product details are provided in the report. Download the Bipolar Depression pipeline report to learn more about the emerging Bipolar Depression therapies at:
https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Pipeline Market Drivers
Demand of new technologies
Increase in the awareness regarding mental disorders
Bipolar Depression Pipeline Market Barriers
Fewer randomized controlled trials (RCTs) of acute Bipolar Depression
Strict pricing and reimbursement policies

Get a Free Sample PDF Report to know more about Bipolar Depression Pipeline Assessment- https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of Bipolar Depression Pipeline Drug Insight
Coverage: Global
Key Bipolar Depression Companies: Clexio Biosciences, Iltoo Pharma, SAGE Therapeutics, NeuroRx, Inc., Sumitomo Dainippon Pharma, and others
Key Bipolar Depression Therapies: CLE-100, ILT101, Zuranolone, NRX101, NRX100, Inc., SEP-4199, and others
Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers

Table of Contents
1 Bipolar Depression Report Introduction
2 Bipolar Depression Executive Summary
3 Bipolar Depression Overview
4 Bipolar Depression- Analytical Perspective In-depth Commercial Assessment
5 Bipolar Depression Pipeline Therapeutics
6 Bipolar Depression Late Stage Products (Phase II/III)
7 Bipolar Depression Mid Stage Products (Phase II)
8 Bipolar Depression Early Stage Products (Phase I)
9 Bipolar Depression Preclinical Stage Products
10 Bipolar Depression Therapeutics Assessment
11 Bipolar Depression Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Bipolar Depression Key Companies
14 Bipolar Depression Key Products
15 Bipolar Depression Unmet Needs
16 Bipolar Depression Market Drivers and Barriers
17 Bipolar Depression Future Perspectives and Conclusion
18 Bipolar Depression Analyst Views
19 Appendix
20 About DelveInsight

Download Sample PDF Report to know more about Bipolar Depression drugs and therapies- https://www.delveinsight.com/sample-request/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.